ADIL
Income statement / Annual
Last year (2024), Adial Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Adial Pharmaceuticals, Inc.'s net income was -$13.20 M.
See Adial Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$565.00
|
$564.00
|
$60.50 K
|
$55.11 K
|
$564.00
|
$565.00
|
$563.00
|
$565.00
|
$565.00
|
$565.00
|
| Gross Profit |
$0.00
|
-$564.00
|
-$60.50 K
|
-$55.11 K
|
-$564.00
|
-$565.00
|
-$563.00
|
-$565.00
|
-$565.00
|
-$565.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$3.23 M
|
$1.27 M
|
$4.18 M
|
$8.40 M
|
$5.85 M
|
$3.97 M
|
$368.46 K
|
$182.11 K
|
$146.14 K
|
$322.11 K
|
| General & Administrative Expenses |
$5.06 M
|
$5.62 M
|
$9.14 M
|
$9.34 M
|
$5.07 M
|
$4.28 M
|
$6.62 M
|
$813.18 K
|
$264.66 K
|
$497.15 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.06 M
|
$5.62 M
|
$9.14 M
|
$9.34 M
|
$5.07 M
|
$4.28 M
|
$6.62 M
|
$813.18 K
|
$264.66 K
|
$497.15 K
|
| Other Expenses |
$0.00
|
-$0.00
|
$0.00
|
$46.49 K
|
$2.50 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$8.28 M
|
$6.89 M
|
$13.32 M
|
$17.74 M
|
$10.93 M
|
$8.24 M
|
$6.99 M
|
$995.29 K
|
$410.81 K
|
$819.26 K
|
| Cost And Expenses |
$0.00
|
$6.89 M
|
$13.32 M
|
$17.74 M
|
$10.93 M
|
$8.24 M
|
$6.99 M
|
$995.29 K
|
$410.81 K
|
$819.26 K
|
| Interest Income |
$178.66 K
|
$69.78 K
|
$63.34 K
|
$6.54 K
|
$32.50 K
|
$95.23 K
|
$7.39 K
|
$367.00
|
$240.00
|
$1.26 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.17 M
|
$144.54 K
|
$9.64 K
|
$0.00
|
| Depreciation & Amortization |
$565.00
|
$564.00
|
$564.00
|
$55.11 K
|
$564.00
|
$565.00
|
$563.00
|
$565.00
|
$565.00
|
$565.00
|
| EBITDA |
-$13.20 M |
-$7.00 M |
-$13.32 M |
-$19.46 M |
-$10.93 M |
-$8.15 M |
-$6.98 M |
-$994.35 K |
-$410.00 K |
-$817.43 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$4.91 M
|
-$113.94 K
|
$585.21 K
|
-$1.82 M
|
$35.00 K
|
-$346.53 K
|
-$4.64 M
|
-$144.17 K
|
-$9.39 K
|
$1.26 K
|
| Income Before Tax |
-$13.20 M
|
-$7.00 M
|
-$12.73 M
|
-$19.52 M
|
-$10.89 M
|
-$8.59 M
|
-$11.63 M
|
-$1.14 M
|
-$420.20 K
|
-$817.99 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$502.00
|
-$94.08 K
|
-$32.50 K
|
-$76.06 K
|
-$3.48 M
|
$367.00
|
$9.64 K
|
$1.26 K
|
| Net Income |
-$13.20 M
|
-$7.00 M
|
-$12.73 M
|
-$19.42 M
|
-$10.86 M
|
-$8.59 M
|
-$11.63 M
|
-$1.14 M
|
-$420.20 K
|
-$817.99 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.71 |
-4.92 |
-11.98 |
-26.12 |
-21.79 |
-21.8 |
-61.1 |
-5.2 |
-2.2 |
-4.28 |
| EPS Diluted |
-0.71 |
-4.91 |
-11.98 |
-26.12 |
-21.79 |
-21.8 |
-61.1 |
-5.2 |
-2.2 |
-4.28 |
| Weighted Average Shares Out |
$18.59 M
|
$1.42 M
|
$1.06 M
|
$743.55 K
|
$498.53 K
|
$394.10 K
|
$190.37 K
|
$218.99 K
|
$191.13 K
|
$191.28 K
|
| Weighted Average Shares Out Diluted |
$18.59 M
|
$1.42 M
|
$1.06 M
|
$743.55 K
|
$498.53 K
|
$394.10 K
|
$190.37 K
|
$218.99 K
|
$191.13 K
|
$191.28 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
